AI in Healthcare: Transforming Early Detection of Nonalcoholic Fatty Liver Disease
Discover how AI detects Metabolic Dysfunction-Associated Steatotic Liver Disease early using imaging, NLP, and liquid biopsy to improve liver health outcomes. The medical community is at the global level experiencing an immense shift in the treatment of steatotic liver disease, which is associated with metabolic dysfunction and, as it was previously referred to, as nonalcoholic fatty liver disease (NAFLD). This change is not simply linguistic, but a complete restructuring of the identification, staging, and treatment of chronic liver conditions. By 2024, the prevalence of MASLD in the adult population of the United States is estimated at 30 percent, and the prevalence rates are steadily increasing in line with outbreaks of obesity and type 2 diabetes (T2DM) worldwide. The main problem with the control of this silent pandemic is the possibility of asymptomatic form of the disease at the initial stages. The build-up of hepatic fat is not even noticeable to the patient, and by the time it...